azacitidine has been researched along with vidarabine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Mak, TW; Wan, CW | 1 |
| Breitman, TR; Cooney, DA; Dalal, M; del Campo, AA; Driscoll, JS; Johns, DG; Plowman, J; Schuller, HM; Vistica, DT | 1 |
| Duley, JA; Fabianowska-Majewska, K; Ruckemann, K; Simmonds, HA | 1 |
| Fabianowska-Majewska, K; Wyczechowska, D | 1 |
| Czyz, M; Fabianowska-Majewska, K; Wyczechowska, D | 1 |
| Fabianowska-Majewska, K; Krawczyk, B | 1 |
| Fabianowska-Majewska, K; Krawczyk, B; Rudnicka, K | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
3 trial(s) available for azacitidine and vidarabine
| Article | Year |
|---|---|
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine | 2017 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
12 other study(ies) available for azacitidine and vidarabine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Inhibition of murine sarcoma virus-induced foci formation by cytidine analogues and other drugs chemotherapeutically effective in human malignancies.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line; Cell Survival; Cell Transformation, Viral; Dose-Response Relationship, Drug; Rats; Sarcoma Viruses, Murine; Vidarabine | 1979 |
Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.
Topics: Animals; Azacitidine; Cell Cycle; Cell Differentiation; Cell Survival; Cells, Cultured; Humans; Mice; Microscopy, Electron; Neoplasm Transplantation; Neoplasms, Experimental; Vidarabine | 1986 |
Effect of Cladribine, fludarabine, and 5-aza-deoxycytidine on S-adenosylmethionine (SAM) and nucleotides pools in stimulated human lymphocytes.
Topics: Adenine Nucleotides; Adenine Phosphoribosyltransferase; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cladribine; Cytidine Triphosphate; Decitabine; Guanine Nucleotides; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; NAD; Ribonucleotides; S-Adenosylmethionine; Uracil Nucleotides; Vidarabine | 1998 |
Does 2-chlorodeoxyadenosine contribute to alteration of DNA methyltransferase activity?
Topics: Adenosylhomocysteinase; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cladribine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hydrolases; Kinetics; Leukemia L1210; Mice; Tumor Cells, Cultured; Vidarabine | 1998 |
Evidence of inhibition of DNA methylation by fludarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cell Line; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Vidarabine | 2000 |
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Topics: Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; Estrogen Receptor alpha; Genes, APC; Genes, BRCA1; Humans; K562 Cells; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Vidarabine | 2006 |
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Genes, APC; Genes, BRCA1; Genes, Tumor Suppressor; Humans; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Vidarabine | 2007 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |